One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 850,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Tuesday, as the share price of this fund traded was up 7% in the day’s session. Its share price is still negative over the past year.

ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 846,189 shares of Takeda. At Tuesday’s closing price, this would have valued this sale at roughly $11.7 million. This is only a small fraction of the total holdings. This fund is down 32% over the past 52 weeks.

Here is a quick look at all the trades that took place across all ARK ETFs:

Fund	Direction	Ticker	Name	Shares
ARKF	Buy	DSYSJ	DISCOVERY	55,621
ARKG	Buy	SGFY	SIGNIFY HEALTH	160,234
ARKG	Sell	TAK	TAKEDA PHARMACEUTICAL	846,189
ARKK	Buy	SGFY	SIGNIFY HEALTH	313,766
ARKK	Buy	TDOC	TELADOC HEALTH	63,567
ARKK	Sell	EDIT	EDITAS MEDICINE	138,796
ARKQ	Buy	BLDE	BLADE AIR MOBILITY	11,926

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use